Inozyme Pharma Management
Management criteria checks 2/4
Inozyme Pharma's CEO is Doug Treco, appointed in Apr 2023, has a tenure of 1.58 years. total yearly compensation is $5.30M, comprised of 7.1% salary and 92.9% bonuses, including company stock and options. directly owns 0.035% of the company’s shares, worth $62.87K. The average tenure of the management team and the board of directors is 2.5 years and 6.6 years respectively.
Key information
Doug Treco
Chief executive officer
US$5.3m
Total compensation
| CEO salary percentage | 7.1% |
| CEO tenure | 1.6yrs |
| CEO ownership | 0.03% |
| Management average tenure | 2.5yrs |
| Board average tenure | 6.6yrs |
Recent management updates
Recent updates
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?
Nov 17
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?
Aug 03Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion
Jul 30Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?
Apr 11Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward
Mar 08Inozyme Pharma GAAP EPS of -$0.38
Aug 15Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency
Jul 19Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?
Jul 12We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
Apr 06Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation
Dec 22Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth
Sep 08We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
May 22Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency
May 07We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely
Feb 06
Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder
Jan 04Inozyme Pharma (INZY) Investor Presentation - Slideshow
Dec 03Inozyme Pharma EPS misses by $1.02
Nov 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$96m |
| Jun 30 2024 | n/a | n/a | -US$89m |
| Mar 31 2024 | n/a | n/a | -US$77m |
| Dec 31 2023 | US$5m | US$375k | -US$71m |
| Sep 30 2023 | n/a | n/a | -US$68m |
| Jun 30 2023 | n/a | n/a | -US$68m |
| Mar 31 2023 | n/a | n/a | -US$68m |
| Dec 31 2022 | US$106k | n/a | -US$67m |
| Sep 30 2022 | n/a | n/a | -US$67m |
| Jun 30 2022 | n/a | n/a | -US$65m |
| Mar 31 2022 | n/a | n/a | -US$62m |
| Dec 31 2021 | US$188k | n/a | -US$57m |
| Sep 30 2021 | n/a | n/a | -US$49m |
| Jun 30 2021 | n/a | n/a | -US$63m |
| Mar 31 2021 | n/a | n/a | -US$60m |
| Dec 31 2020 | US$339k | n/a | -US$56m |
Compensation vs Market: Doug's total compensation ($USD5.30M) is above average for companies of similar size in the US market ($USD1.46M).
Compensation vs Earnings: Doug's compensation has increased whilst the company is unprofitable.
CEO
Doug Treco (66 yo)
1.6yrs
Tenure
US$5,299,476
Compensation
Dr. Douglas A. Treco, also known as Doug, Ph D., is an Advisor at LSV Capital Management LLC. Earlier he was a Scientific Advisor at the firm.He was Chief Executive Officer of Alchemab Therapeutics from A...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 1.6yrs | US$5.30m | 0.035% $ 62.9k | |
| Co-Founder | no data | US$1.80m | 0.42% $ 749.4k | |
| Senior VP | 2.7yrs | US$1.03m | 0.047% $ 85.4k | |
| Senior VP & COO | 1.6yrs | US$1.55m | 0.0076% $ 13.8k | |
| Co-Founder | no data | no data | no data | |
| Senior VP & Chief Technical Operations Officer | 2.7yrs | no data | no data | |
| Senior VP | 1.8yrs | no data | no data | |
| Director of Investor Relations | no data | no data | no data | |
| Senior VP & Chief People Officer | 3.3yrs | no data | no data | |
| Chairman of Scientific Advisory Board & Senior VP | no data | no data | no data | |
| Consultant | 2.7yrs | no data | no data | |
| Senior VP & Chief Medical Officer | 2.4yrs | no data | no data |
2.5yrs
Average Tenure
58.5yo
Average Age
Experienced Management: INZY's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 4.5yrs | US$5.30m | 0.035% $ 62.9k | |
| Co-Founder | 9.2yrs | US$1.80m | 0.42% $ 749.4k | |
| Co-Founder | no data | no data | no data | |
| Chairman of Scientific Advisory Board & Senior VP | no data | no data | no data | |
| Independent Director | 7.2yrs | US$129.65k | 0% $ 0 | |
| Lead independent director | 7.8yrs | US$130.27k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | US$135.00k | no data | |
| Independent Director | 7.8yrs | US$116.15k | 0% $ 0 | |
| Independent Director | 6yrs | US$112.15k | 0% $ 0 | |
| Independent Director | 5.7yrs | US$114.65k | 0% $ 0 | |
| Independent Director | 4.5yrs | US$122.15k | 0% $ 0 | |
| Chairperson of Clinical Advisory Board | no data | no data | no data |
6.6yrs
Average Tenure
64yo
Average Age
Experienced Board: INZY's board of directors are considered experienced (6.6 years average tenure).